Spectral AI Adds Additional Clinical Sites to Multi-Center Diabetic Foot Ulcer (DFU) Study
16 Ottobre 2023 - 2:00PM
Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) (“Spectral AI” or
the “Company”), an artificial intelligence (AI) company
focused on medical diagnostics for faster and more accurate
treatment decisions in wound care, today announced the addition of
seven clinical sites that are currently enrolling to support the
development of its diabetic foot ulcer (DFU) application for the
DeepView® Wound Imaging System. The proprietary technology combines
multi-spectral imaging and AI technology to provide clinicians with
an immediate healing assessment of DFU’s for more accurate and
timely diagnosis and therapeutic intervention.
Participating investigators and clinical sites include:
- Dr. Tony Alleman, MD, University of
Tennessee Health Science Center
- Dr. Ian Barron, DPM, Gentle Foot
Care Hilliard and Gentle Foot Care Grove City
- Dr. Stephen Frania, DPM, Foot and
Ankle Specialist of Ohio
- Dr. Vladimir Zeetser, DPM, Premium
Podiatry and Wound Care
- Dr. Charles Ananian, DPM, New Hope
Podiatry Group
- Dr. Karl Fulkert, DPM, Worthington
Foot and Ankle
“We are pleased to announce the addition of seven additional
clinical sites that will provide valuable data for Spectral AI’s
DeepView® AI algorithm development,” said Mary Regan, PhD, VP of
Clinical Affairs at Spectral AI. “We have selected leading wound
care providers for these sites as we have done in the past. I look
forward to advancing our DeepView® Wound Imaging technology and
acquiring high quality data for this study.”
The data collected from these additional sites will be
incorporated to bolster the database for the development of the DFU
healing prediction algorithm using the Company's DeepView®
technology and support the Company’s applications for FDA, UKCA,
and CE mark approval for DeepView®’s DFU indication.
“The potential integration of AI imaging technology into our
medical practice represents an advancement in patient care,” said
Brian Inkrott, Founding Partner of Statera. “This cutting-edge tool
could enable us to quickly diagnose and monitor wound healing with
greater accuracy and efficiency, paving the way for tailoring
treatments more precisely to each patient's needs.”
DFU is a severe chronic diabetic complication that consists of
lesions in the deep tissues associated with neurological disorders
and peripheral vascular disease in the lower limbs. It is the most
frequently recognized, complex and costly symptom of diabetes that
can lead to limb amputation if left undiagnosed, misdiagnosed, or
untreated. Due to U.S. reimbursement rules, physicians are
currently required to wait 30 days to designate a DFU as
non-healing before using advanced wound care therapies, resulting
in higher probability of infections, longer healing times and
significant lifetime medical costs for the patient. DeepView®’s
early healing assessment for DFU has the potential to provide a
significant improvement to the current standard of care, resulting
in faster application of advanced therapy when needed, better wound
healing, and reduced overall hospital visits.
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company
focused on medical diagnostics for faster and more accurate
treatment decisions in wound care, with initial applications
involving patients with burns and diabetic foot ulcers. The Company
is working to revolutionize the management of wound care by “Seeing
the Unknown®” with its DeepView® System. DeepView® is a predictive
diagnostic device that offers clinicians an objective and immediate
assessment of a wound’s healing potential prior to treatment or
other medical intervention. With algorithm-driven results and a
goal of substantially exceeding the current standard of care in the
future, DeepView® is expected to provide faster and more accurate
treatment insight towards value care by improving patient outcomes
and reducing healthcare costs. For more information about
DeepView®, visit www.spectral-ai.com.
Forward Looking Statements Certain statements
made in this release are “forward looking statements” within the
meaning of the “safe harbor” provisions of the United States
Private Securities Litigation Reform Act of 1995, including
statements regarding the Company’s strategy, plans, objectives,
initiatives and financial outlook. When used in this press release,
the words “estimates,” “projected,” “expects,” “anticipates,”
“forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,”
“will,” “should,” “future,” “propose” and variations of these words
or similar expressions (or the negative versions of such words or
expressions) are intended to identify forward-looking
statements.
These forward-looking statements are not guarantees of future
performance, conditions, or results, and involve a number of known
and unknown risks, uncertainties, assumptions and other important
factors, many of which are outside Company’s control, that could
cause actual results or outcomes to differ materially from those
discussed in the forward-looking statements. As such, readers are
cautioned not to place undue reliance on any forward-looking
statements.
Investors should carefully consider the foregoing factors and
the other risks and uncertainties described in the “Risk Factors”
sections of the Company’s filings with the SEC, including the
Registration Statement and the other documents filed by the
Company. These filings identify and address other important risks
and uncertainties that could cause actual events and results to
differ materially from those contained in the forward-looking
statements.
Contacts:
Investors:Spectral AIChristine
Marks VP Marketing and Commercialization
ir@spectral-ai.com
The Equity Group Devin Sullivan Managing
Directordsullivan@equityny.com
Conor Rodriguez Analyst crodriguez@equityny.com
Media: Russo Partners David
Schull Russo Partners (858) 717-2310
david.schull@russopartnersllc.com
Guillermo Ruiz, M.D., Ph.D. Russo Partners (646) 218-4604
guillermo.ruiz@russopartnersllc.com
Grafico Azioni Spectral AI (NASDAQ:MDAI)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Spectral AI (NASDAQ:MDAI)
Storico
Da Set 2023 a Set 2024